FDA grants breakthrough therapy status for Celladon' heart failure treatment ... Pharmaceutical Business Review The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Celladon's lead product candidate, Mydicar, for reducing hospitalisations for heart failure in NYHA class III or IV chronic heart failure patients who are NAb ... FDA Grants “Breakthrough Therapy” Status for Gene Therapy to reduce Systolic ... |
